nelivaptan (BH-200) / HMNC Brain Health - LARVOL DELTA

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder (GlobeNewswire) - "HMNC Brain Health...announced today the successful completion of patient randomization for its Phase 2b OLIVE trial. The trial is investigating the efficacy and safety of BH-200, a potent vasopressin V1b receptor antagonist, alongside a predictive companion diagnostic in patients with Major Depressive Disorder (MDD)....Initial results from the OLIVE trial are expected in Q2 2025."

P2b data • Trial status • Major Depressive Disorder